<DOC>
	<DOC>NCT01105533</DOC>
	<brief_summary>This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.</brief_summary>
	<brief_title>A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically or cytologically confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy. At least 1 measurable disease site as defined by Response Evaluation Criterion in Solid Tumors [RECIST]. Adequate bone marrow, liver function and renal function as defined by protocol. Blood pressure Requirements During dose escalation no evidence of preexisting hypertension and no antihypertensive medications at baseline. During dose expansion patient's whose hypertension is controlled by antihypertensive therapy. Chemotherapy, radiotherapy or any investigational therapy within 4 weeks of study entry Current use or anticipated need for drugs that are known CYP34 inhibitors or inducers. Patients with carcinomatous meningitis or untreated brain metastases. Any acute cardiovascular incident within the past 12 months. Patients with active gastrointestinal bleeding or significant gastrointestinal abnormalities as defined by protocol Patients with no evidence of the following for 5 years: malignancy or metastatic disease of skin cancer (except melanoma), in situ cervical cancer or breast cancer or T1C prostate cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>VGEF inhibitor</keyword>
	<keyword>Anti angiogenesis</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>